ARDX

Ardelyx's stock price has been impacted by several events over the past six months. A downturn followed the Q4 2025 earnings report due to XPHOZAH reimbursement issues. The company reported a net loss of $0.15 per share for Q1 2026, missing analyst estimates, and experienced rising operating expenses. However, the stock surged after the Q1 2026 earnings report due to strong revenue growth and reiterated guidance. Presentation of long-term safety data for XPHOZAH at the National Kidney Foundation's Spring Clinical Meetings could positively influence investor sentiment. The stock has traded between $3.21 and $8.40 over the past 52 weeks.